Skip to main content
. Author manuscript; available in PMC: 2017 Dec 7.
Published in final edited form as: Vaccine. 2016 Nov 12;34(50):6402–6407. doi: 10.1016/j.vaccine.2016.09.061

FIG 2.

FIG 2

Immunogenicity and protective efficacy of AT62 in a murine surgical wound infection model. (A) Mice were immunized on days 0, 14, and 28 with 20 μg AT62 or BSA + MPL. Serum samples were diluted 1:100, and antibody levels to native Hla were measured by ELISA. (B) Mice actively immunized with AT62 or BSA had surgical site wounds inoculated with 3 μl containing 176 to 300 CFU S. aureus LAC. Three days after bacterial challenge, quantitative cultures were performed on homogenized tissues to determine the bacterial burden. The data are pooled from two independent experiments. (C) Mice were passively immunized by the IP route with 1 mg of rabbit AT62 IgG or naïve IgG and challenged 24 h later with 43 to 92 CFU S. aureus LAC. Quantitative cultures were performed after 3 d on homogenized tissues to determine the bacterial burden. Horizontal lines represent group medians, and dashed lines represent lower limit of detection by culture. *, P <0.05; **, P <0.01, determined by the Mann Whitney test.